Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Synergy Rx vs Gala Health

Synergy Rx
Graded #39

Lower grade

vs+9.799999999999997
Gala Health
Graded #10

Higher grade

The verdict

Gala Health takes it — 86/100 to 76.2/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.

We may earn a commission if you start care through some of these links, at no extra cost to you. Affiliate partners are listed first — a capped 3-point edge in board order only. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +28
62
90
Dose & formulationSynergy Rx +5
88
83
Clinical oversightSynergy Rx +7
92
85
Labs & monitoringGala Health +17
66
83
FulfillmentGala Health +10
78
88
Contract termsGala Health +18
68
86
Synergy Rx · left barGala Health · right bar

The numbers

MetricSynergy RxGala Health
WeighScore76.2/10086/100
GradeCB
Scorecard rank#39#10
SemaglutideFrom $199/moNot disclosed
TirzepatideFrom $349/mo$179/mo
CoverageNot disclosedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Synergy Rx

Graded #39 · C

Strengths

  • Prescribes FDA-approved brand Wegovy, Ozempic and Mounjaro when clinically appropriate
  • Unlimited appointments, unlimited messaging and 24/7 access to a dedicated clinical team
  • $100 welcome credit at checkout, and FSA/HSA eligible

Where it loses points

  • Publishes no GLP-1 price anywhere on its own site
  • At $349/mo tirzepatide sits roughly $100 above the compounded median we track
  • Does not publish which states it serves
  • No published cancellation or refund terms
Gala Health

Graded #10 · B

Strengths

  • Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
  • Available in all 50 states
  • Keeps a brand-name path open (Ozempic listed at $1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 43 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard